Intravesical Gemcitabine For Superficial Bladder Cancer
Australian investigators tested the treatment in a Phase II trial that enrolled 54 patients. Intravesical gemcitabine (2000 mg) was administered one hour every week for six consecutive weeks. Of 44 patients evaluable for response, 16 (36%) had a complete response (no evidence of tumor, negative cytology) and 17 (39%) had a partial response (positive cytology with negative cystocscopy or reduced tumor bulk). Seven patients (16%) had stable disease and four (9%) progressed.
Toxicities were mild and urinary; no systemic or hematologic toxicity greater than grade 1 occurred.
Findings were reported here at the 2008 Genitourinary Cancers Symposium.